Ofatumumab is a novel anti-CD20 monoclonal antibody recently approved for the treatment of chronic lymphocytic leukemia refractory to alemtuzumab and fludarabine. Ofatumumab has also demonstrated activity in other low-grade non-Hodgkin's lymphomas. However, the optimal time to use ofatumumab and in what patient population is debatable. This article will review some of the key clinical studies that led to the drug's approval, current recommended usage of the drug and significant future directions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1586/eci.11.15 | DOI Listing |
Publication Analysis
Top Keywords
low-grade non-hodgkin's
8
non-hodgkin's lymphomas
8
chronic lymphocytic
8
lymphocytic leukemia
8
ofatumumab
4
ofatumumab treatment
4
treatment low-grade
4
lymphomas chronic
4
leukemia ofatumumab
4
ofatumumab novel
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!